34 results on '"Gasparyan, Samvel B."'
Search Results
2. Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
3. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
4. Clinical trial designs to assess treatment effects on glomerular filtration rate decline
5. Adjusted Win Ratio with Stratification: Calculation Methods and Interpretation
6. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression
7. Validity and Utility of a Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression: A Review
8. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
9. Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
10. Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.
11. Basic Data Structure for Hierarchical Composite Endpoints: An Application to Kidney Disease Trials
12. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
13. Development and Validation of a New Hierarchical Composite Endpoint for Clinical Trials of Kidney Disease Progression
14. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials
15. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
16. Effect of Dapagliflozin on Total Heart Failure Events in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction:A Prespecified Analysis of the DELIVER Trial
17. The maraca plot: A novel visualization of hierarchical composite endpoints
18. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction
19. Comments on “Sample size formula for a win ratio endpoint” by R. X. Yu and J. Ganju
20. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
21. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
22. Dapagliflozin across the range of ejection fraction in patients with heart failure:a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
23. The maraca plot: A novel visualization of hierarchical composite endpoints.
24. Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply
25. sj-pdf-1-ctj-10.1177_17407745221134949 – Supplemental material for The maraca plot: A novel visualization of hierarchical composite endpoints
26. Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials.
27. Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials
28. Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study
29. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction:An Analysis of DAPA-HF
30. Adjusted win ratio with stratification: Calculation methods and interpretation
31. Adjusted win ratio with stratification: Calculation methods and interpretation.
32. Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials.
33. On Approximation of the BSDE with Unknown Volatility in Forward Equation.
34. Dapagliflozin in patients with COVID-19: mind the kidneys – Authors' reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.